CRMD vs SUPN
CRMD: CorMedix is a commercial-stage biopharmaceutical company focused on preventing catheter-related bloodstream infections and providing a portfolio of essential hospital-based infectious disease therapies. SUPN: A neuroscience-focused biopharmaceutical company dedicated to developing and commercializing innovative therapies for complex central nervous system disorders.
Side-by-side fundamentals
| Metric | CRMD | SUPN | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $7.60 | $46.98 | |
| Market cap as of 2026-07-31 | $564M | $2.7B | |
| P/E as of 2026-07-31 | 3.12 | n/a | |
| PEG as of 2026-07-31 | 0.00 | n/a | |
| Net margin as of 2026-07-31 | +45.3% | -3.7% | CRMD higher |
| Gross margin as of 2026-07-31 | +85.8% | +89.7% | SUPN higher |
| Operating margin as of 2026-07-31 | +48.4% | -7.8% | CRMD higher |
| ROE as of 2026-07-31 | +50.4% | -2.7% | CRMD higher |
| ROA as of 2026-07-31 | +27.4% | -2.0% | CRMD higher |
| Debt / equity as of 2026-07-31 | 0.33 | 0.00 | SUPN lower |
| Revenue growth (YoY) as of 2026-07-31 | +384.6% | +16.3% | CRMD higher |
| Revenue CAGR (3y) SEC XBRL | +535.6% | +2.5% | CRMD higher |
| Beta as of 2026-07-31 | 1.52 | 0.56 | |
| 1-year return as of 2026-07-27 close | -33.9% | +39.9% | SUPN higher |
Fundamentals: market data, as of 2026-07-31. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.